Современные критерии прогноза в комплексной диагностике первичных опухолей костей (клинико-морфологическое исследование)
Диссертация
Исследователи полагают, что предпосылкой для активации неоангиогенеза в опухолях является размножение и миграция эндотелиальных клеток, которые подобно опухолевым клеткам продуцируют протеазы и локально инвазируют базальную мембрану и периваскулярный внеклеточный матрикс, формируя новую капиллярную сеть в опухоли (С.В.Луценко и соавт., 2004; Kushlinskii N. et al., 2000). Среди ангиогенных… Читать ещё >
Список литературы
- Абелев Г. И., Эрайзер Т. Л. На пути к пониманию природы рака // Биохимия.-2008.- том 73, № 5.-с.605−618.
- Алиев М.Д., Соловьев Ю. Н., Харатишвили Т. К., Мусаев Э. Р., Соколовский В. А. Хондросаркома кости // М.-ИНФРА-М.-2006.-216с.
- Алиев М.Д. Современные подходы к хирургическому лечению больных с метастатическим поражением позвоночника//Саркомы.-2010.-№ 3.-с.З-9.
- Алиев М.Д. Злокачественные опухоли костей // М.: Издательская группа РОНЦ 2008.-408 е.: 187 ил.
- Бритвин Т.А. Первичные опухоли надпочечников: оценка клинико-морфологических и биохимических критериев диагностики и факторов прогноза // Автореф.дисс. .докт.мед.наук.-М.-2006.
- Гафтон Г. И., Гудзь Ю. В. Хирургическое лечение сарком таза // Практическая онкология.-2010.-том 11, № 1.-с.25−30.
- Герштейн Е.С., Щербаков A.M., Гончаров Д. Ю. и соавт. Фактор роста эндотелия сосудов при раке пищевода // Вопросы биологической, медицинской и фармацевтической химии.-2004.-№ 1.-с.26−29.
- Герштейн Е.С., Щербаков A.M., Обушева М. Н., Кушлинский Н. Е. Иммуноферментное исследование содержания фактора роста эндотелия сосудов (VEGF) в опухолях и сыворотке крови больных раком молочной железы //Кремлевская медицина.-2005.-№ 3.-с.45−52.
- Головков Д.А. Клиническая значимость ключевых маркеров ангиогенеза, апоптоза, системы активации плазминогена в сыворотке крови и опухоли больных колоректальным раком // Автореф.дисс.докт.мед.наук.-М.-2009.-48с.
- Горбунова В.А. Этюды химиотерапии // М.-«Литтерра». -2006.-376с.
- Гуревич Л.Е. Роль экспрессии матриксной металлопротеиназы-2 и компонентов экстрацеллюлярного матрикса коллагена IV типа и ламинина в определении инвазивного потенциала новообразований поджелудочной железы // Архив патол.-2003.-том 65, № 5.-с.21−25.
- Давиденко И.С., Пефти Е. Б., Фокин А. Н. Значение ангиогенеза в терапии метастатического рака молочной железы // Российский биотерапевтический журнал.-2007.-№ 4.-с.8−12.
- Егоренков В.В. Пограничные и доброкачественные опухоли костей // Практическая онкология.-2010.-том 11, № 1.-с.37−44.
- Жуков Н.В., Тюляндин С. А. Целевая терапия в лечении солидных опухолей: практика противоречит теории // Биохимия.-2008.-том 73, вып.5.-с.751−768.
- Карамышева А.Ф. Ангиогенез опухоли: механизмы, новые подходы к терапии / В кн. «Канцерогенез» под ред. Д. Г. Заридзе // М.-Научный Мир.-2000.-C.298−309.
- Киселев С.М., Луценко C.B., Северин С. Е., Северин Е. С. Ингибиторы опухолевого ангиогенеза//Биохимия.-2003.-том 68, № 5.-с.611−631.
- Копнин Б.П. Генетическая нестабильность клеток: роль дисфункции белков Ras и р53 / В материалах Российской конференции по фундаментальной онкологии «Петровские чтения 2005» (Санкт-Петербург, 15 апреля 2005 г.) // Сн.-Петербург.-2005.-с.12
- Крживицкий П.И. Клинико-лучевая диагностика сарком костей // Практическая онкология.-2010.-том 11, № 1.-с.11−18.
- Кузнецов И.Н. Факторы ангиогенеза в сыворотке крови больных саркомами костей // Автореф.дисс.канд.биол.наук.-М.-2009.-27с.
- Кузнецова О.М., Березов Т. Т., Кушлинский Н. Е. Фактор роста эндотелия сосудов. Особенности секреции в костной ткани. Норма и патология // Вопросы медицинской химии.-2003.-том 49, № 3.-с.360−373.
- Кушлинский Н.Е. Молекулярно-биологические исследования при опухолях костей / В кн.: «Злокачественные опухоли костей» (под ред. М.Д.Алиева) Издательская группа РОНЦ им. Н. Н. Блохина РАМН // М.-2008.-с. 19−54.
- Луценко C.B., Киселев С. М., Фельдман Н. Б., Северин С. Е. Молекулярные механизмы ангиогенеза в физиологических и патологических процессах / В кн.: Введение в молекулярную медицину (под ред. М.А.Пальцева) // М.-Медицина.-2004.-с.446−495.
- Луценко C.B., Фельдман Н. Б., Северин С. Е. Перспективы противоопухолевой антиангиогенной терапии // Молекулярная медицина.-2004.-№ 4.-с. 13−24.
- Мацко Д.Е. Саркомы костей: классификация, гистологическое строение, особенности морфологической диагностики // Практическая онкология.-2010.-том 11, № 1.-с.1−10.
- Мачак Г. Н. Современные возможности лекарственной терапии остеосарком // Практическая онкология.-2010.-том 11, № 1.-с.31−36.
- Мусаев Э.Р. Первичные опухоли позвоночника // Практическая онкология.-2010.-том 11, № 1.-с.19−24.
- Нейштадт Э. Л. Маркочев А.Б. Опухоли и опухолеподобные заболевания костей // -СПб: ООО.-Издательство «Фолиант». -2007.-344с.
- Переводчикова Н.И. Таргетные препараты и их место в современной терапии опухолевых заболеваний // 0нкогематология.-2009.-том 2, № 4.-с.367−373.
- Полушкина И.Н., Степанова Е. В., Дбар Ж. Н. Молекулярно-биологические маркеры, характеризующие апоптоз, пролиферацию иангиогенез при раке яичников // Вестник РОНЦ им. Н. Н. Блохина РАМН.-2004-№ 4.-с.60−64.
- Семенова А.И. Саркома Юинга: характеристика заболевания, особенности диагностики, лечебная тактика // Практическая онкология.-2010.-ТОМ 11, № 1.-с.45−52.
- Соколовский В.А. Злокачественная фиброзная гистиоцитома кости (клиника, диагностика, лечение) // Автореф. дисс.докт.мед.наук.-М.-1999.
- Соловьев Ю.Н. Опухоли и опухолеподобные поражения скелета (опыт изучения 4899 наблюдений) // Вестник ОНЦ РАМН. 1998. — № 1. — с. 13−18.
- Соловьев Ю.Н. Новые нозологические формы в классификации опухолей костей // Архив патологии. 1998. — том 60, № 4. — с.57−61.
- Соловьев Ю.Н. Опухоли костей: классификация, номенклатура, проблемы диагностики //Архив патологии.-2003.-том 65, № 5.-C.3−6.
- Франк Г. А., Завалишина Л. Э., Андреева Ю. Ю. Уточняющая диагностика рака с использованием иммуногистохимического определения маркеров // М.-ФГУ МНИОИ им. П. А. Герцена Росмедтехнологий.-2009.-12с.
- Вестник РОНЦ им. Н. Н. Блохина РАМН. Статистика злокачественных новообразований в России и странах СРГ в 2007 г. № 3. том 20, приложение 1, 2009.
- Adler С.Р., Herget G.W., Neuburger М. Cartilaginous tumors: prognostic applications of cytophotometric DNA analysis // Cancer.-1995.-Vol.76.-p.1176−1180.
- Ahmed A.R., Tan T.S., Unni К К. et al. Secondary chondrosarcoma in osteochondroma: report of 107 patients // Clin. Orthop. Relat. Res.-2003.-Vol.411 .-p. 193−206.
- Ahmed A.R., Tan T.S., Unni K.K., Collins M.S., Wenger D.I., Sim F.H. Secondary chondrosarcoma in osteochondroma: report of 107 patients // Clin Orthop Relat Res/2003 Jun:(41 l).-p. 193−206.
- Ahn J., Ludecke H.J., Lindow S., Horton W.A., Lee В., Wagner M.J., Horsthemke В., Wells D.E. Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1) //Nat. Genet.-1995.-Vol.1 l.-p, 137−143.
- Aigner Т., Unni K.K. Is dedifferentiated chondrosarcoma a 'de-differentiated' chondrosarcoma? // J. Pathol.-1999.-Vol.l89.-p.445−447.
- Akatsuka Т., Wada Т., Kokai Y. et al. Erb2 expression is correlated withincreased survival of patients with osteosarcoma // Cancer.-2002.-Vol.94.-p.1397−1404.
- Akatsuka T., Wada T., Kokai Y. et al. oss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma // Oncology.-200l.-Vol.60.-p.361−366.
- Alho A., Skjeldal S., Melvik J.E., Pattersen E.G., Larsen T.E. The clinical importance of DNA synthesis and aneuploidy in bone and soft tissue tumors // Anticancer Res.-1993 .-Vol. 13 .-p.2383−23 87.
- Ambros I.M., Ambros P.F., Strehl S. et al. MIC2 is a specific marker for Ewing’s sarcoma and PNET // Cancer.-199l.-Vol.67.-p. 1886−1993.
- Amling M., Neff L., Tanaka S. et al. Bcl-2 lies downstream of parathyroid hormone-related peptide in a signaling pathway that regulates chondrocyte maturation during skeletal development // J. Cell Biol.-1997.-Vol.l36.-p.205−213.
- Amling M., Posl M., Hentz M.W., Priemel M., Delling G. PTHrP and Bcl-2: essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors // Verh. Dtsch. Ges. Pathol.-1998.-Vol.82.-p.l60−169.
- Andela V.B., Gordon A.H., Zotalis G. et al. NFDappaB: a pivotal transcription factor in prostate cancer metastasis to bone // Clin. Orthop. Relat. Res.-2003.-S.75−85.
- Anderson D.R. Ultrastructure of hyaline and elastic cartilage of the rat // Am. J. Anat.-1964.-Vol.l 14.-p.403−434.
- Angervall L., Persson S., Stenman G., Kindblom L.G. Large cell, epithelioid, telangiectatic osteoblastoma: a unique pseudosarcomatous variant of osteoblastoma // Hum. Pathol.-1999.-Vol.30.-p. 1254−1259.
- Anninga J.K., van de Vijver M.J., Cleton-Jansen A.M. et al. Overexpression of the HR-2 oncogene does not play a role in high-grade osteosarcoma // Eur. J. Cancer.-2004.-Vol.40-p.963−970.
- Anninga J.K., van de Vijver M.J., Cleton-Jansen A.M. et al. Overexpression of the HR-2 oncogene does not play a role in high-grade osteosarcoma // Eur. J. Cancer.-2004.-Vol.40-p.963−970.
- Antonescu C.R., Argani P., Erlandson R.A. Healey J.H., Ladanyi M., Huvos A.G. Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study // Cancer.-1998.-Vol.83.-p.1504−1521.
- Ayala G., Liu C., Nicosia R., Horowitz S., Lackman R. Microvasculature and VEGF expression in cartilaginous tumors // Hum. Pathol.-2000.-Vol.31.-p.341−346.
- Bacci G., Picci P., Mercuri M., Bertoni F., Ferrary S. Neoadjuvant chemotherapy for high grade malignant fibrous histiocytoma of bone // Clin Orthop.-1998.-Vol.346.-p. 178−89.
- Bajpai J., Sharma M., Sreenivas V., Kumar R., Gamnagatti S., Khan S.A., Rastogi S., Malhotra A., Bakhshi S. VEGF expression as a prognostic marker in osteosarcoma //Pediatr. Blood Cancer.-2009.-Vol.53, N.6.-p.l035−1039.
- Bakhshi S., Gupta A., Sharma C. et al. Her-2neu, P-53, and their coexpression in osteosarcoma//Pediatr. Hematol. Oncol.-2009.-Vol.31, N.4.-p.245−251.
- Balasubramanian L., Evens A.M. Targeting angiogenesis for the treatment of sarcoma//Curr. Opin. Oncol.-2006.-Vol.l8.-p.354−359.
- Baldini N., Scotlandi K., Barbanti-Brodano G. et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome // N. Engl. J. Med.-1995.-Vol.333.-p. 1380−1385.
- Baldini N., Scotlandi K., Serra M. et al. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy // J. Orthop. Res.-1999.-Vol.l7.-p.629−632.
- Barr F.G. Translocations, cancer and the puzzle of specificity // Nat. Genet.-1998.-Vol.19.-p. 121−124.
- Barr F.G., Ladanyi M. Sarcomas, In: Leonard DGB, ed. Diagnostic Molecular Pathology. Philadelphia: Saunders: 2003- 53−76.
- Baruffi M.R., Volpon J.B., Neto J.B., Casartelli C. Osteoid osteoma with chromosome alterations involving 22q // Cancer Genet. Cytogenet.-2001.-Vol.124.-p. 127−131.
- Bassett D.E.Jr., Eisen M.B., Bogurski M.S. Gene expression informatics it’s all in your mind//Nat. Genet.-1999.-21(Suppl.).-p.51−55.
- Bayani J., Zielenska M., Pandita A. et al. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8,17, and 20 in osteosarcomas // Genes Chromosomes Cancer.-2003.-Vol.36.-p.7−16.
- Belchis D.A., Meece C.A., Rogan P.K., Williams R.A., Gocke C.D. Loss of heterozygosity and microsatellite instability at the retinoblastoma locus in osteosarcomas //Diagn. Mol. Pathol.-1996.-Vol.5.-p.214−219.
- Bellaiche Y., The I., Perrimon N. Tout-velu is a Drosophila homologie of the putative tumour suppressor EXT-1 and is needed for Hh diffusion // Nature.-1998.-Vol.394.-p.85−88.
- Benassi M.S., Molendini L., Gamberi G. et al. Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma // Cancer.-2001 .-Vol.92.-p.3062−3067.
- Benassi M.S., Molendini L., Gamberi G. et al. Alterarion of pRb/pl6/cdk4 regulation in human osteosarcoma // Int. J. Cancer.-1999.-Vol.84.-p.489−493.
- Bennett W.P., Hollstein M.C., Hsu I.C. Mutational spectra and immunohistochemical analyses of p53 in human cancers // Chest.-1992.-Vol. 101 (Suppl.3).-19S-20.
- Bennicelli J.L., Barr F.G. Chromosomal translocations and sarcomas // Curr. Opin. Oncol.-2002.-Vol. 14.-p.412−419.
- Bernard M.A., Hall C.E., Hogue D.A. et al. Diminished levels of the putative tumor suppressor proteins EXT1 and EXT2 in exostosis chondrocytes // Cell Motil. Cytoskeleton.-2001 .-Vol.48 .-p. 149−162.
- Bertoni F., Bacchini P., Staals E.L., Davidovitz P. Dedifferenmtiated parosteal osteosarcoma: the experience of the Rizzoli Institute // Cancer.-2005.-Vol. 103. N. 11 .-p.2373−2382.
- Bertoni F., Unni K.K., Lucas D.R. et al. Osteoblastoma with cartilaginous matrix. An unusual morphologic presentation in 18 cases // Am. J. Surg. Pathol.-1993 .-Vol. 17.-p.69−74
- Bishop F.G. Viral oncogenes // Cell.-1985.-Vol.42.-p.23−38.
- Bjornsson J., McLeod R.A., Unni K.K., Ilstrup D.M., Pritchard D.J. Primary chondrosarcoma of long bones and limb girdles // Cancer.-1998.-Vol.83.-p.2105−2119.
- Bodey B., Groger A.M., Bodey B.Jr., Siegel S.E., Kaiser H.E. Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas // Anticancer Res.-1997.-Vol.l7.-p.493−498.
- Bookstein R., Shew J.Y., Chen P.L., Scully P., Lee W.H. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene // Science.-1990.-Vol.247.-p.712−715.
- Bos J.M. The ras gene family and human carcinogenesis // Mutat. Res.-1988.-Vol. 195.-p.255−271.
- Bovee J.V., Cleaton-Jansen A.M., Kuipers-Dijkshoorn N.J. et al. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma // Genes Chromosomes Cancer. -1999.-Vol.26.-p.237−246.
- Brandwood C.P., Hoyland J.A., Hillarby M.C. et al. Apoptotic gene expression in Paget’s disease: apossible role for Bcl-2 // J. Pathol.-2003.-Vol.20l.-p.504−512.
- Bridge J.A., Bhatia P. S., Anderson J.R., Neff J.R. Biologic and clinical significance of cytogenetic and molecular cytogenetic abnormalities in benign and malignant cartilaginous lesions // Cancer Genet. Cytogenet.-1993.-Vol.69.-p.79−90.
- Bridge J.A., Persons D.L., Neff J.R., Bhatia P. Clonal karyotypic aberrations in enchpndromas // Cancer Detect Prev.-1992.-Vol.l6.-p.215−219.
- Bridge J.A., Sandberg A.A. Cytogenetics. In: Damyanov I., Linder J., eds. Anderson’s pathology vol.1, 10th ed. St. Louis: Mosby Year Book, Inc- 1996.-p.223−257.
- Brody R.I., Ueda T., Hamelin A. et al. Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma //Am. J. Pathol.-1997.-Vol. 150.-p. 1049−1058.
- Bubendorf L., Nocito A., Moch H. et al. Tissue microray (TMA) technology: miniaturized pathology archives for high throughput in situ studies // J. Pathology.-2001.-Vol. 195.-p.72−79.
- Buddingh E.P., Naumann S., Nelson M., Neff J.R., Birch N., Bridge J.A. Cytogenetic findings in benign cartilaginous neoplasms // Cancer Genet. Cytogenet.-2003 .-Vol. 141 -p. 164−168.
- Burchill S.A. Ewing’s sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities // J. Clinical Pathology.-2003.-Vol.56.-p.96−102.
- Cahan W.G. Radiation-induced sarcoma- 50 years later // Cancer.-1998.-Vol.83, N.5.-p.l048−1049.
- Cahan W.G., Woodard H.Q., Higinbotham N.L., Stewart F.W., Coley B.L. Sarcoma arising in irradiated bone: report of eleven cases // Cancer 1998 Jan l-82(l):8−34.
- Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases // Nature.-2000.-Vol.407.-p.249−257.
- Carmeliet P., Moons L., Lijnen R. et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation // Nat. Genet.-1997.-Vol.l7.-p.439−444.
- Caroll K.L., Yandow S.M., Ward K., Carey J.C. Clinical correlation to genetic variations of hereditary multiple exostosis // J. Pediatr. Orthop.-1999.-Vol. 19.-p.785−791.
- Casperson T., Zech L., Johansson C. Differential binding of alkalating fluorochromes in human chromosomes // Exp. Cell Res.-1970.-Vol.60.-p.315−319.
- Castresana J.S., Barrios C., Gomez L., Kreicbergs A. Amplification of the c-myc proto-oncogene in human chondrosarcoma // Diagn. Mol. Pathol.-1992.-Vol.l.-p.235−238.
- Cavazzana A.O., Miser J.S., Jefferson J., Triche T.J. Experimantal evidence for a neural origin of Ewing’s sarcoma of bone // Amer. J. Pathology.-1987.-Vol. 127.-p.507−518.
- Chan H.S., Grogan T.M., Haddad G., DeBoer G., Ling V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy // J. Natl. Cancer Inst.-1997.-Vol.89.-p.l706−1715.
- Chan S.L., Yu V.C. Proeins of the Bcl-2 family in apoptosis signaling: from mechanistic insights to therapeutic opportunities // Clin. Exp. Pharmacol. PHysiol.-2004.-Vol.31.-p.l 19−128.
- Chandar N., Donehower L., Lanciloti N. Reduction in p53 gene dosage diminishes differentiation capacity of osteoblasts // Anticancer Res.-2000.-Vol.20.-p.2553−2559.
- Chano T., Ikegawa S., Kontani K., Okabe H., Baldini N., Saeki Y. Identification of RB1CC1, a novel human gene that can induce RBI in various human cells // Oncogene.-2002.-Vol.21.-p.l295−1298.
- Chen Y., Sasatomi E., Satoh T. Abnormal distribution of collagen type IV in extrahepatic bile duct carcinoma //Pathol. Int.-2000.-Vol.5, N. l l.-p.884−890.
- Chen Y.J., Wei Y.Y., Chen H.T. et al. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-DBdependent pathway in human chondrosarcoma cells // J.* Cell Physiol.-2009.-Vol.221, N.l.-p.98−108.
- Chene P., Bechter E. p53 mutants without a functional tetramerisation domain are not oncogenic // J. Mol. Biol.-1999.-Vol.286.-p.l269−1274.
- Cheung V.G., Morley M., Aguilar F., Massimi A., Kucherlapati R., Childs G. Making and reading microarrays //Nat. Genet.-1999.-21 (Suppl.).-p.l5−19.
- Chow W.A. Update on chondrosarcomas // Curr. Opin. Oncol.-2007.-Vol. 19.-p.371−376.
- Chu J., Lloyd F.L., Trifan O.C. et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer // Mol. Cancer Ther.-2003.-Vol.2.-p.l-7.
- Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia // Am. J. Pathol.-1995.-Vol.l47.-p.545−560.
- Coughlan B., Feliz A., Ishida T., Czerniak B., Dorfman H.D. p53 expression and DNA ploidy of cartilage lesions // Hum. Pathol.-1995.-Vol.26.-p.620−624.
- Dahlen A., Mertens F., Rydholm A. et al. Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas // Mod. Pathol.-2003.-Vol.16.-p.1132−1140.
- Dahlin D. Grading of bone tumors // Semin. Diagn. Pathol.-1984.-Vol.l.-p. 165.
- Dal Cin P., Rao U., Yurc-Carel C., Sandberg A.A. Translocation (7−21) in a lipoma // Cancer Genet. Cytogenet.-1988.-Vol.30.-p. 17−22.
- Dalton W.S. Overcoming the multidrug-resistent phenotype. In: DeVita V.T.Jr., Hellman S., Rosenberg S.A., eds. Cancer: principles and practice of oncology, 4th ed. Philadelphia: J.B.Lippincott Company.-1993.-p.2655−2666.
- Davis R.I., Foster H., Arthur K., Trewin S., Hamilton P.W., Biggart D.J. Cell proliferation studies in primary synovial chondromatosis // J. Pathol.-1998.-Vol.184.-p. 18−23.
- Day S.J., Nelson M., Rosenthal H., Vergara G.G., Bridge J.A. Der (16)t (l-16)(q21-ql3) as a secondary structural aberration in yet a third sarcoma, extraskeletal myxoid chondrosarcoma // Genes Chromosomes Cancer.-1997.-Vol.20.-p.425−427.
- Deckers M., Karperien M. et al. Expression of Vascular Endothelial Growth Factor and Treir Receptors during Osteoblast Differentiation // Endocrinology.-2000.-Vol. 141 .-p. 1667−1674.
- De Clerck Y.A., Shimada H., Taylor S.M., Langley K.E. Matrix metalloproteinases and their inhibitors in tumor progression // Ann. New York Acad. Sci. 1994. V. 732. P. 222−232.
- Delattre O., Zuchman J., Plougastel B., Desmaze C., Melot T., Peter M., ovar H., Joubert I. de Jong P., Rouleau G., Aurias A., Thomas G. Gene fusion with an
- ETS DNA-binding domain caused by chromosome translocation in human tumours // Nature.-1992.-Vol.359.-p. 162−165.
- Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis // Cancer Metastasis Rev.-2006.-Vol.25, N.l.-p.9−34.
- Deshpande V., Rosenberg A.E., O’Connell J.X. et al. Epithelioid angiosarcoma of the bone: a series of 10 cases // Am. J. Surg. Pathol.-2003.-Vol.27.-p.709−716.
- Deveraux Q.L., Reed J.C. IAP family proteins supressors of apoptosis // Genes Dev.-1999.-Vol. 13 .-p.239−252.
- Deyrup A.T., Montag A.G., Inwards C.Y. et al. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases // Arch. Pathol. Lab. Med.-2007.-Vol. 131 .-p.942−946.
- Dickens D.S., Kozielski R., Khan J. et al. Cyclooxygenase-2 expression in pediatric sarcomas // Pediatr. Dev. Pathol.-2002.-Vol.5.-p.356−364.
- Dickens D.S., Kozielski R., Leavey PJ. et al. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rabdomyosarcoma // J. Pediatri. Hematol. Oncol.-2003.-Vol.25.-p.282−285.
- Dickey I.D., Rose P. S., Fuchs B. et al. Dedifferentiated chondrosarcoma- the role of chemotherapy with updated outcomes // J. Bone Joint Surg.-2004.-86AQ.-p.2412−2418.
- Do S.L., Araujo E.S., Kalil R.K. et al. Expression of embryonic lethal abnormal vision (ELAV)-like protein HuR and cyclooxygenase-2 (COX-2) in Ewing sarcoma//Tumori.-2008.-Vol.94, N.3.-p.347−350.
- Dobashi Y., Sugimura H., Sato A. et al. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma // Diagn. Mol. Pathol.-1993 .-Vol.2.-p.257−263.
- Dorfman H.D., Czerniak B. eds. Bone Tumors // St. Louis: Mosby: 1998.-p.103−127.
- Dorfman H.D., Wiess S.W. Bordering osteoblastic tumors: problems in the differential diagnosis of aggressive osteoblastoma and low-grade osteosarcoma // Semin. Diagn. Pathol.-1984.-Vol.l.-p.215−234.
- Draper G.J., Sanders B.M., Kingston J.E. Second primary neoplasms in patients with retinoblastoma // Br. J. Cancer.-1986.-Vol.53.-p.661−671.
- Dryja T.P., Cavenee W., White R. et al. Homozygosity of chromosome 13 in retinoblastoma//New Engl. J. Med.-1984.-Vol.310.-p.550−553.
- DuBois S., Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma // Cancer.-2007.-Vol.l09.-p.813−819.
- Ek E.T., Ojaimi J., Kitagawa Y., Choong P.F. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? // Int. Semin. Surg. Oncol.-2006.-Vol.3.-p.7.
- Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multodrug resistence // Ann. Rev. Biochem.-1989.-Vol.58.-p.l37−171.
- Feely M.G., Boehm A.K., Bridge R.S. et al. Cytogenetic and molecular cytogenetic evidence of recurrent 8q24.1 loss osteochondroma // Cancer Genet. Cytogenet.-2002.-Vol. 137.-p. 102−107.
- Fellenberg J., Krauthoff A., Pollandt K. et al. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue // Lab. Invest.-2004.-Vol.84.-p.l 13−121.
- Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors // Nature Medicine.-2003.-Vol.9, N.6.-p.669−676.
- Ferrari S., Bertoni., Zanella L. et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma // Cancer.-2004.-Vol.100.-p. 1936−1942.
- Ferreira C.G., Epping M., Kruyt F.A. et al. Apoptosis: target of cancer therapy // Clin. Cancer Res.-2002.-Vol.8.-p.2024−2034.
- Feugeas O., Guriec N., Babin-Boilletot A. et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma // J. Clin. Oncol.-1996.-Vol.l4.-p.467−472.
- Fletcher C.D., Unni K.K., Mertens F.eds. Pathology and genetics of tumors of soft tissue and bone // Lyon: IARC Press- 2002.
- Fletcher J.A., Gebhardt M.C., Kozakewich H.P. Cytogenetic aberrations in osteosarcomas. Nonrandom deletions, rings, and double-minute chromosomes // Cancer Genet. Cytogenet.-1994.-Vol.77.-p.81−88.
- Fletcher J.A., Lipinski K.K., Weidner N., Morton C.C. Complex cytogenetic aberrations in a well-differentiated chondrosarcoma // Cancer Genet. Cytogenet.-1989.-Vol.41.-p.l 15−121.
- Folkman J. Angiogenesis. In: Harrison’s Textbook of Internal Medicine, 15th Edition. Braunwald E., Fauci A.S., Kasper D.L., Hauser S.L., Longo D.L., Jameson J.L., eds. New York: McGraw-Hill.-2001.-p.517−530.
- Folpe A.L., Inwards C.Y. Bone and soft tissue pathology (A volume in the series foundations in diagnostic pathology. Series editor: J.R.Goldblum) // Saunders Elsevier, Philadelphia.-2010.-462P.
- Francannet C., Cohen-Tanugi A., Le Merrer M., Minnich A., Bonaventure J., Legeai-Mallet L. Genotype-phenotype correlation in heredoatary multiple exostoses // J. Med. Genet.-2001.-Vol.38.-p.430−434.
- Franchi A., Calzolari A., Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton // Virchows Arch.-l 998.-Vol.432.-p.515−519.
- Francke U. Retinoblastoma and chromosome 13 // Bieth Defects Orig Arctic Ser.-l 976.-Vol. 12.-p. 131−134.
- Frassica F.J., Waltrip R.L., Shonseller P.D. (1996) Clinicopathologic features and treatment of osteoid osteoma and osteoblastoma in children annd adolescents // Orthop Clin North Am 27:559−574/
- Friend S.H., Bernards R., Rogelj S. et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma // Nature.-1986.-Vol.323 .-p.643−646.
- Fryns J.P., Heremans G., Marien J., Van der Berghe H. Langer-Giedion syndrome and deletion of the long arm of chromosome 8. Confirmation of the critical segment to 8q23 //Hum. Genet.-1983.-Vol.64.-p.l94−195.
- Fuchs B., Dickey I.D., Yaszemski M.J. et al. Operative management of sacral chordoma // J. Bone Joint Surg. Am.-2005.-Vol.87, N.10.-p.2211−2216.
- Ganawan B., Weber M., Bergmann F. Wildberger J., Niethard F.U., Fusesi L. Clonal chromosome abnormalities in enchondromas and chondrosarcomas // Cancer Genet. Cytogenet.-2000.-Vol.120.-p. 127−130.
- Garrison R.C., Unni K.K., McLeod R.A. Pritchard D.J., Dahkin D.C. Chondrosarcoma arising in osteochondroma // Cancer.-1982.-Vol.49.-p. 1890−1897.
- Gerald W.L. A practical approach to the differential diagnosis of small round cell tumors of infancy using recent scientific and technical advances // Intern. J. Surg. Pathol.-2000.-Vol.8, N.2.-p.87−97.
- Gitelis S., Bertoni F., Picci P., Campanacci M. Chondrosarcoma of bone // J. Bone Joint Serg. Am.-l98l.-Vol.63.-p. 1248−1257.
- Gleason B.C., Leigl-Atzwanger B., Kozakewich H.P. et al. Osteofibrous dysplasia and adamantinoma in children and adolescents: a clinikopathologic reappraisal//Am. J. Surg. Pathol.-2008.-Vol.32.-p.363−376.
- Gokgoz N., Wunder J.S., Mousses S. et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma // Cancer.-2001 .-Vol. 92.-p.2181−2189.
- Gorlick R., Anderson P., Andrulis I. et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary // Clin. Cancer Res.-2003.-Vol.9.-p.5442−5453.
- Gorlick R., Huvos A.G., Heller G. et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma// J. Clin. Oncol.-1999.-Vol.l7.-p.2781−2788.
- Granter S.R., Renshaw A.A., Kozakewich H.P., Fletcher J.A. The pericentromeric inversion, inv (6)(p25ql3), is a novel diagnostic marker in chondromyxoid fibroma // Mod. Pathol.-1998.-Vol.11.-p. 1071−1074.
- Green F.L., Page D.L. Fleming I.D., Fritz A.G., Balch C.M., Haller D.G., Morrow M. AJCC Cancer Staging Manual. 6th ed. Springer: New ork.-2002.
- Greenbatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis // Cancer Res.-1994.-Vol.54.-p.4855−4878.
- Grigioni W.F., Fiorentino M., D’Errico A. et al. Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to being liver conditions // Hepatology.-1995.-Vol.21.-p.l543−1546.
- Grigoriadis A.E., Schellander K., Wang Z.Q. et al. Osteoblast are target cells of transformation in c-fos transgenic mice // J. Cell. Biol.-1993.-Vol.122.-p.685−701.
- Gunawan B., Weber M., Bergmann F., Wildberger J., Niethard F.U., Fuzeri L. Clonal chromosome abnormalities in enchondromas and chondrosarcomas // Cancer Genet. Cytogenet.-2000.-Vol.l20.-p.l27−130.
- Gustafson P., Rydholm A., Willen H et al. Liposarcoma: A population based epidemiologic and prognostic study of features of 43 patients, including DNA content//Int. J. Cancer.-1993.-Vol.55.-p.541.
- Haab B.B. Advances in protein microarray technology for protein expression and interaction profiling // Curr. Opin. Drug Discov. Devel.-2001.-Vol.4.-p.l 16 123.
- Hackel C.G., Krueger S., Grote HJ. et al. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma // Cancer.-2000.-Vol.89.-p.995−1003.
- Halbert A.R., Harrison W.R., Hicks M.J., Davino N., Cooley L.D. Cytogenetic analysis of a scapular chondromyxoid fibroma // Cancer Genet. Cytogenet.-1998.-Vol.l04.-p.52−56.
- Hall R.B., Robinson L.H., Malawar M.M., Dunham W.K. Periosteal osteosarcoma // Cancer.-1985.-Vol.55.-p.l65−171.
- Hansen M.F., Koufos A., Gallie B.L. et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition // Proc. Natl. Acad. Sci USA.-1985.-Vol.82.-p.6216−6220.
- Harbour J.W. Overview of RB gene mutations in patients with retinoblastoma. Implications for clinical genetic screening // Ophthalmology.-1998.-Vol.105.-p.1442−1447.
- Harvey W., Squier M.V., Duance V.C., Pritchard J. Abiochemical and immunohistological study of collagen synthesis in Ewing’s tumour // Br. J. Cancer.-1982.-Vol.46, N.6.-p.848−855.
- Hawkins M.M., Draper G.J., Kingston J.E. Incidence of second primary tumours among childhood cancer survivors // Br. J. Cancer.-1987.-Vol.56.-p.339−347.
- Hazelbag H.M., Fleuren J.G., van den Broek L J. et al. Adamantinoma of long bones: keratin subclass immunoreactivity pattern with reference to its histogenesis //Am. J. Surg. Pathol.-1993.-Vol. 17.-p. 1225−1233.
- Hecht J.T., Hogue D., Wang Y. et al. Hereditary multiple exostoses (EXT): mutational studies of familial EXT1 cases and EXT-associated malignancies // Am. J. Hum. Genet.-1997.-Vol.60.-p.80−86.
- Heiser D., Labi V., Erlacher M, et al. The Bcl-2 protein family and its role in the development of neoplastic disease // Exp/ Gerontol.-2004.-Vol.39.-p.1125−1135.
- Helio H., Karaharju E., Bohling T., Kivioja A., Nording S. Chondrosarcoma of bone. A clinical and DNA flow cytometric study // Eur. J. Surg. Oncol.-1995.-Vol.21.-p.408−413.
- Herschman H.R. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2 // Cancer Metastasis Rev.-1994.-Vol.l3.-p.241−256.
- Hisaoka M., Ishida T., Imamura T., Hashimoto H. TGF is a novel fusion partner of NOR1 in extraskeletal myxoid chondrosarcoma // Genes Chromosomes Cancer.-2004.-Vol.40.-p.325−328.
- Hoang B.H., Dyke J.P., Koutcher J.A., Huvos A.G., Mizobuchi H., Gorlick R., Healey J.H. VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI // Clin. Orthop. Relat. Res.-2004.-p.38−32.
- Hoch B.L., Nielsen G.P., Liebsh N.G. et al. Base of skull chordomas in children and adolescents- a clinicopathologic study of 73 cases // Am. J. Surg. Pathol.-2006.-Vol.30, N.70.-p.811−818.
- Hopyan S., Gokgaz N., Poon R. et al. A mutant PHT/PTHrP type 1 receptor in enchondromatosis //Nat. Genet.-2002.-Vol.30.-p.306−310.
- Huang H.J., Yee J.K., Shew J.Y. et al. Supression of the neoplastic phenotype by replacement of the RB gene in human cancer cells // Science.-1988.-Vol.242.-p.1563−1566.
- Huang H-Y., Illei P.B., Zhao Z. et al. Ewing’s sarcoma with p53 mutation or pl6/pl4ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse//J. Clin. Oncol.-2005.-Vol.23, N.3.-p.548−558.
- Huang Y., Lin Z., Zhuang J., Chen Y., Lin J. Prognostic significance of alpha V integrin and VEGF in osteosarcoma after chemotherapy // 0nkologie.-2008.-Vol.31.-p.535−540.
- Hudis C.A. Transtuzumab mechanism of action and use in clinical practice // N. Engl. J. Med.-2007.-Vol.357-p.39−51.
- Huvos A.G. Chondrosarcoma and its variants // J. Orthop. Sci.-1996.-Vol.1.-p.90−97.
- Inoue Y.Z., Frassica F.J., Sim F.H., Unni K.K., Petersen I.A., McLeod R.A. Clinicopathologic features and treatment of postirradiation sarcoma of bone and soft tissue // J. Surg. Oncol.-2000.-Vol.75.-p.42−50.
- Ishida T., Kikuchi F., Machinami R. Histological grading and morphometric analysis of cartilaginous tumors // Virchows Arch.-1991.-Vol.418.-p. 149−155.
- Jaffe E.S., Harris N.L., Stein H., Vardiman J.W., eds. Pathology and genetics of tumours of haematopoetic and lymphoid tissues // Lyon: LARC Press.-2001.
- Jain D., Jain V.K., Vasishta R.K. et al. Adamantinoma: a clinicopatholigical review and update // Diagn. Pathol.-2008.-Vol.3.-p.8.
- Jones K.B., Morcuende J.A. Of hedgehogs and hereditary bone tumors: reexamination of the pathogenesis of osteochondromas // Iowa Orthop. J.-2003.-Vol.23.-p.87−95.
- Judson I. In relation to Anninga et al. overexpression of the HER-2 oncogene does not play role in high-grade osteosarcomas // Eur. J. Cancer.-2004.-Vol.40.-p.924−925.
- Juuti A., Louhimo J., Nordling S. et al. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer // J. Clin. Pathol.-2006.-Vol.59.-p.382−386.
- Kallioniemi A., Kallioniemi O.P., Sudar D. et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors // Science.-1992.-Vol.25 8.-p.818−821.
- Kamb A. Cyclin-dependent kinase inhibitors and human cancer // Curr. Top. Microbiol. Immunol.-1998.-Vol.227.-p. 139−148.
- Kan P., Schmidt M.H. Osteoid osteoma and osteoblastoma of the spine // Neurosurg Clin. N. Am.-2008.-Vol.l9.-p.65−70.
- Kanoe H., Nakayama T., Murakami H. et al. a mplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation // Anticancer Res.-1998.-Vol. 18.-p.2317−2321.
- Kansara M., Thomas D.M. Molecular pathogenesis of osteosarcoma. DNA // Cell Biol.-2007.-Vol.26.-p.l-18.
- Kaseta M.-K.A., Khaldi L., Gomatos LP. et al. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma // J. Surg.-Oncol.-2007.-Vol.97, Iss.3.-p.259−266.
- Kawashima A., Okada Y., Nakanishi I., Ueda Y., Iwata K., Roessner A. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas // Gen. Diagn. Pathol.-1997.-Vol.142.-p. 129−137.
- Keeney G.L., Unni K.K., Beabout J.W. et al. Adamantinoma of long bones. A clinicopathologic study of 85 cases//Cancer.-1989.-Vol.64.-p.730−737.
- Khan J., Wei J.S., Ringner M. et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neutral networks // Nat. Med.-2001 .-Vol.7.-p.673−679.
- Khanna C., Khan J., Nguyen P. et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma // Cancer Res.-2001.-Vol.61.-p.3750−3759.
- Kilpatrick S E Diagnostic Musculoskeletal Surgical Pathology: clinicoradiologic and cytologic correlations/copyright 2004, Elsevier, Inc (USA).
- Kilpatrick S.E., Renner J.B., Creager A. Diagnostic musculoskeletal surgical pathology. Clinicoradiologic and cytologic correlation ., Elsevier, Inc (USA), 2004.
- Kilpatrick S.E., Geisinger K.R., King T.S. et al. Clinicopathologic analysis of HER-2/neu immunoezpression amang various histologic subtupes and grades of osteosarcoma //Mod. Pathol.-2001/-Vol.l4.-p.l277−1283.
- Kivioja A., Ervasti H., Kinnunen J., Kaitil i., Wolf M., Bohling T. Chondrosarcoma in a family with multiple hereditary exostoses // J. Bone Joint Surg. Br.-2000.-Vol.82.-p.261−266.
- Kleer C.G., Unni K.K., McLeod R.A. Epithelioid hemangioendothelioma of bone//Am. J. Surg. Pathol.-1996.-Vol.20.-p.l301−1311.
- Klenke F.M., Gebhard M.-M., Ewerbeck V. et al. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice // BMC Cancer.-2006.-Vol.6.-p.9.
- Kmijo T., Zindy F., Roussel M.F. et al. Tumor suppression of the mouse INK4a locus mediated by the alternative reading frame product pl9ARF // Cell.-1997.-Vol.91 .-p.649−659.
- Knudson A.G.Jr. Mutation and cancer: statistical study of retinoblastoma // Proc. Natl. Acad. Sci. USA.-1971.-Vol.68.-p.820−823.
- Kondo T., Ohta T., Igura K. et al. Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding // Cancer Lett.-2002.-Vol. 180, N.2.-p.l39−144.
- Kosmeyer S.J. Bcl-2 initiates a new category of oncogenes: regulators of cell death // Blood.-1992.-Vol.80.-p.879−886.
- Kovar H. Context matters: the hen or egg problem in Ewing’s sarcoma. Seminars in Cancer Biology // Seminars in Cancer Biology.-2005.-Vol. 15.-p. 189 196.
- Kreicbergs A., Boquist L., Borssen B., Larsson S.E. Prognostic factors in chondrosarcoma: a comparative study of cellular DNA content and clinicopathologic features // Cancer.-1982.-Vol.50.-P.577−583.
- Kunze E., Enderle A., Radig K., Schneider-Stock R. Aggressive osteoblastoma with focal malignant transformation and development of pulmonary metastases. A case report with a review of literature // Gen. Diagn. Pathol.-1996.-Vol.141.-p.377−392.
- Kurt A.M., Unni K.K., McLeod R.A., Pritchard D.J. Low-grade intraosseus osteosarcoma //Cancer.-1990.-Vol.65.-p. 1418−1428.
- Kushlinskii N., Babkina I., Solov’ev Y., Trapeznikov N. Vascular endothelial growth factor and angiogenin in the serum of patients with osteosarcoma and Ewing’s tumor//Bull Exp. Biol. Med.-2000.-Vol.l30.-p.691−693.
- LaBaer J. Genomics, proteomics, and the new paradigm in biomedical research // Genet. Med.-2002.-4(Suppl.).-2S-9.
- Ladanyi M., Gerald W.L. Present and potential impact of expression profiling studies of human tumors. In: Ladanyi M., Gerald W.L., eds. Expression profiling of human tumors. Diagnostic and research applications. Totawa N.J.: Huvana Press.-2003.-p.3−7.
- Ladanyi M., Gerald W.L. Present and potential impact of expression profiling studies of human tumors. In: Ladanyi M., Gerald W.L., eds. Expression profiling of human tumors. Diagnostic and research applications. Totawa N.J.: Humana Press.-2003.-p.3−7.
- Laga A.C., Zander D.S., Cagle P.T. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer // Arch. Pathol. Lab. Med.-2005.-Vol.l29.-p.l 113−1117.
- Lambert P.F., Sugden B. Viruses in cancer. In: Abeloff M., Armitage J., Niederhuber J., Kastan M., McKenna W., eds. Clinical oncology, 3rd ed. New York: Elsevier.-2004.-p.207−225.
- Lander E.S. Array of hope // Nat. Genet.-1999.-21 (Suppl.)
- Larramendy M.L., Mandahl N., Mertens F. et al. Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomas //Hum. Pathol.-1999.-Vol.30.-p.l247−1253.
- Le Doussal V., Coindre J.M., Leroux A et al. Prognostic factors for patients with localized primary malignant histiocytoma: A multicenter study of 216 patients with multivariate analysis // Cancer.-1996.-Vol.77.-p.1823.
- Le Merrer M., Legeai-Mallet L., Jeannin P.M. et al. A gene for hereditary multiple exostoses maps to chromosome 19p // Hum. Mol. Genet.-1994.-Vol.3.-p.'717−722.
- Lee W.H., Bookstein R., Hong F., Young L.J., Shew J.Y., Lee E.Y. Human retinoblastoma susceptibility gene: cloning, identification, and sequence // Science.-1987.-Yol.235 .-p. 13 94−13 99.
- Leenders W., Lubsen N., Altena M. et al. Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flk-1 and Flt-1 // Lab. Invest.-2002.-Vol.82.-p.473−481.
- Levine A.J. The tumor suppressor genes // Ann. Rev. Biochem.-1993.-Vol.62.-p.623−651.
- Li W.W., Fan J., Hochhauser D., Bertino J.R. Overexpression of p21wafl leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells // Cancer Res.-1997.-Vol.57.-p.2193−2199.
- Limon J., Debiec-Rychter M., Nedoszytko В., Liberski P.P., Babinska M., Szadowska A. Aberrations of chromosome 22 and polysomy of chromosome 8 as non-random changes in clear cell sarcoma // Cancer Genet. Cytogenet.-1994.-Vol.72.-p. 141−145.
- Lin C., Meitner P.A., Terek R.M. PTEN mutation is rare in chondrosarcoma // Diagn. Mol. Pathol.-2002.-Vol. 11 .-p.22−26.
- Lind Т., Tufaro F. VcCormick C., Lindahl U., Lidholt K. The putative tumor supressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparin sulfate // J. Biol.Chem.-1998.-Vol.273.-p.26 265−26 268.
- Link M.P., Gebhardt M.C., Meyers P.A. Osteosarcoma. In: Pizzo P.A., Poplack D.G., editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins- 2006.-p.l074−1115.
- Llombart-Bosch A. Ewing’s sarcoma and Primitive Neuroectodermal Tumor of Bone and soft tissue // Int. J. Surg. Pathol.-1999.-Vol.7, N.4.-p. 185−192.
- Llombart-Bosch А. Лекция IV конгресс патоморфологов, московская область пос. Нахабино 19−22 Мая 2009.
- Lopes-Guerrero J.A., Pellin A., Noguera R. et al. Molecular analysis of the 9p21 locus and h53 genes in Ewing’s family tumors // Lab. Invest.-2001.-Vol.81.-p.802−814.
- Lowe S.W., Bodis S., McClatchey A. et al. p53 status and efficacy of cancertherapy in vivo II Science.- 1994.-Vol.266.-p.807−810.
- Lucas D.R.Unni K.K., McLeod R.A., 'Connor M.I., Sim F.H. Osteoblastoma: clinicopathologic study of 306 cases //Hum. Pathol.-1994.-Vol.25.-p.l 17−134.
- Ludecke H.J., Johnson C., Wagner M.J. et al. Molecular definition of the shortest region of deletion overlap in the Langer-Giedion syndrome // Am. J. Hum. Genet.-1991.-Vol.49.-p. 1197−1206.
- Lurje G., Zhang W., Schultheis FA.M. et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer // Ann. 0ncology.-2008.-Vol. 19.-p. 1734−1741.
- Macgregor P.F., Squire J.A. Application of microarrays to the analysis of gene expression in cancer// Clin. Chem.-2002.-Vol.48.-p. 1170−1177.
- Maciag A., Sithanandam G., Anderson L.M. Mutant K-rasV12 increases COX-2, peroxides and DNA damage in lung cells // Carcinogenesis.-2004.-Vol.25.-p.2231−2237.
- Maeda T., Kawane T., Horiuchi N. Statins Augment Vascular Endothelial Growth Factor Expression in Osteoblastic Cells via Inhibition of Protein Prenylation // Endocrinology.-2003.-Vol.l44.-p.681−692.
- Maitra A., Roberts H., Weinberg A. et al. Aberrant expression of tumor suppressor proteins in the Ewing’s family tumors // Arch. Pathol. Lab. Med.-2001.-Vol.125.-p. 1207−1212.
- Maitra A., Wanzer D., Weinberg A.G. et al. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcoma// Cancer.-2001.-Vol.92.-p.677−683.
- Mandahl N., Gustafson P., Mertens F. et al. Cytogenetic aberrations and their prognostic impact in chondrosarcoma // Genes Chromosomes Cancer.-2002.-Vol.33.-p. 188−200.
- Mandahl N., Willen H., Rydholm A., Heim S., Mitelman F. Rearrangement of band ql3 on both chromosomes 12 in a periosteal chondroma // Genes Chromosomes Cancer.-1993.-Vol.6.-p.l21−123.
- Mankin H.J., Cantley K.P., Lippiello L., Schiller A.L., Campbell C.J. The biology of human chondrosarcoma. I. Description of the cases, grading, and biochemical analyses // J. Bone Joint Surg. Am.-1980.-Vol.62.-p.l60−176.
- Mankin H.J., Cantley K.P., Schiller A.L., Lippiello L. The biology of human chondrosarcoma. II. Variation in chemical composition among types and subtypes of bening and malignant cartilage tumors // J. Bone Joint Surg. Am.-1980.-Vol.62.-p.176−188.
- Mankin H.J., Connor J.F., Schiller A.L. et al. Grading of bone tumors by analysis of nuclear DNA content using flow cytometry // J. Bone Join Surg.-1985.-Vol.67(A).-P.404−413.
- Mankin H.J., Hornicek F.J., Rosenberg A.E. et al. Survival data for 648 patients with osteosarcoma treated at one institution // Clin. Orthop. Relat. Res.-2004.-Vol.429.-p.286−291.
- Marina N., Gebhardt M., Teot L. et al. Biology and therapeutic advances for pediatric osteosarcoma//Oncologist.-2004.-Vol.9.-p.422−441.
- Marina N., Gebhardt M., Teot L. et al. Biology and therapeutic advances for pediatric osteosarcoma // Oncologist.-2004.-Vol.9.-p.422−441.
- Mark J., Wedell В., Dahlenfors R., Grepp C., Burian P. Human benign chondroblastoma with a pseudodiploid stemline characterized by a complex and balanced translocation // Cancer Genet. Cytogenet.-1992.-Vol.58.-p.l4−17.
- Martin M.D., Matrisian L.M. The other side of MMPs: protective roles in tumor progression // Cancer Metastasis Rev.-2007.-Vol.26.-p.717−724.
- Marx J. Medicine. DNA arrays reveal cancer in its many forms // Science.-2000.-Vol.289.-p. 1670−1672.
- Mascarello J.T., Krous H.F., Carpenter P.M. Unbalanced translocation resulting in the loss of the chromosome 17 short arm in an osteoblastoma // Cancer Genet. Cytogenet.-1993.-Vol.69.-p.65−67.
- Mascarello J.T., Krous H.F., Carpenter P.M. Unbalanced translocation resulting in the loss of the chondrosarcoma 17 shot arm in an osteoblastoma // Cancer Genet. Cytogenet.-1993.-Vol.69.-p.65−67.
- Masi L., Recenti R., Silvestri S. et al. Expression of cyclooxygenase-2 in osteosarcoma of bone // Appl. Immunohistochem. Mol. Morphol.-2007.-Vol.15, N.l.-p.70−76.
- Matrisian L.M. Matrix metalloproteinase gene expression // Arm. New York Acad. Sci.-1994.-Vol.732.-p.42−50.
- McCarty M.F., Block K.I. Multifocal Angiostatic Therapy // Integrative Cancer Therapies.-2005.-Vol.4, N.4.-p.301−314.
- McCoemick C., Leduc Y., Martindale D. et al. The putative tumour suppressor EXT1 alters the expression of cell-surface heparin surfate // Nat. Genet.-1998.-Vol.l9.-p.l 58−161.
- McGrory J.E. Опухоли при остеомиелите. McGrory J.E., Pritchard D.J., Unni K.K., Ustrup D., Rowland C.M. Malignant lesions arising in chronic osteomyelitis: a follow-up study // Clin. Orthop.-1999.-Vol.362.-p.l81−189.
- McLeod R.A., Berquist Т.Н. Bone tumor imaging: contribution of CT and MRI. Contemp Issues Surg Pathol 1988- 11:1−34.
- Meis-Kindnblom J.M., Stenman G., Kingblom L.-G. Differential diagnosis od small round cell tumors // Semin. In Diagn. Pathol.-1996.-Vol.13, N.3.-p.213−241.
- Mendlick M.R., Nelson M., Pickering D. et.al. Translocation t (l-3)(p36-q25) is a nonrandom aberration in epithelioid hemangioendothelioma // Am. J. Surg. Pathol.-2001.-Vol.25.-p.684−687.
- Mercuri M., Picci P., Campanacci L., Rulli E. Dedifferentiated chondrosarcoma// Skeletal Radiol.-1995.-Vol.24.-p.409−416.
- Mertens F., Jonsson K., Willen H. et al. Chromosome rearrangements in synovial chondromatosis //Br. J. Cancer.-1996.-Vol.74.-p.251−254.
- Milgram J.W. Intraosseus lipomas. A clinicopathologic study of 66 cases // Clin. Orthop.-1988.-Vol.23-p.277−302.
- Milgram J.W. The origins of osteochondromas and enchondromas // Clin. Orthop. Rel. Res.-1983 .-Vol. 174.-p.264−284.
- Millauer B., Shawver L.K., Plate K.H. et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant//Nature.-1994.-Vol.367.-p.576−579.
- Miller C.W., Aslo A., Won A. et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma// J. Cancer Res. Clin. Oncol.-1996.-Vol.l22.-p.559−565.
- Min Y.K., Rao Y., Okada Y. et al. Regulation of prostaglandin G/H synthase-2 expression by interleukin in human osteoblast-like cells // J. Bone Miner. Res.-1998.-Vol.13.-p. 1066−1075.
- Mirra J.M. Bone Tumors. Clinical, Radiologic, and Pathologic Correlations. Lea&Febiger: Philadelphia (1989).
- Mirra J.M., Brien E.W. Giant notochordal hamartoma of intraosseous origin: a newly reported benign entity to be diatinquished from chordoma. Report of two cases // Skeletal Radiol.-2001.-Vol.30.-p.698−709.
- Mitelman F., Johansson C., Mertens F., eds. Mitelman database of chromosome aberrations in cancer (2004) Updated 5−26−04. Retrieved July 27, 2004, from World Wide Web: http: // cgap.nci.nih.gov / Chromosomes / Metelman.
- Moalic S., Liagre B., Le Bail J.C., Beneytout J.L. Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor // Int. J. Oncol.-2001.-Vol.18.-p.533−540.
- Moghal N., Sternberg P.W. Multiple positive and negative regulators of signaling by the EGF-receptor // Curr. Opin. Cell Biol.-1999.-Vol.l 1, N.2.-p.l90−196.
- Muller Y., Li B., Christinger H., Wells J. et al. Vascular Endothelial Growth Factor: Crystal structure and functional mapping of the kinase domain receptor binding site // Biochemistry.-1997.-Vol.94.-p.7192−7197.
- Mullins M.N., Lana S.E., Dernell W.S. et al. Cyclooxygenase-2 expression in canine appendicular asteosarcomas // J. Vet. Intern. Med.-2004.-Vol.l8.-p.859−865.
- Murphy G., Docherty A.J. The matrix metalloproteinases and their inhibitors // Am. J. Respir. Cell Molecul. Biol.- 1992.-Vol.7.-p. 120−125.
- Naka T., Iwamoto Y., Shinohara N., Ushijima M., Chuman H., Tsuneyoshi M. •Expression of c-met protooncogene product (c-MET) in bening and malignant bone tumors // Mod. Pathol.-1997.-Vol.l0.-p.832−838.
- Nakase M., Inui M., Okumura K. et al. P53 gene therapy of human osteosarcoma using a transferring-modified cationic liposome // Mol. Cancer Ther.-2005.-Vol.4, N.4.-p.625−631.
- Naumann S., Krallman P.A., Unni K.K., Fidler M.E., Neff J.R., Bridge J.A. Translocation der (13−21)(ql0-ql0) in skeletal and extraskeletal mesenchymal chondrosarcoma // Mod. Pathol.-2002.-Vol.l5.-p.572−576.
- Nawa G., Ueda T., Mori S. et al. Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas // Internat. J. Cancer.-1996.-Vol.69.-p.86−91.
- Nedelcu T., Kubista., Koller A. et al. Livin and Bcl-2 expression in high-grade osteosarcoma//J. Cancer Res. Clin. Oncol.-2008.-Vol.l34.-p.237−244.
- Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications // J. Clin. Oncol.-2000.-Vol.18, N.5.-p.l 135−1149.
- Nielsen G.P., Burns K.L., Rosenberg A.E., Louis D.N. CDKN2A gene deletions and loss of pi6 expression occur in osteosarcomas that lack RB alterations //Am. J. Pathol.-1998.-Vol.l53.-p.l59−163.
- Nishio J., Gentry J.D., Neff .R. et al. Monoallelic deletion of the p53 gene through chromosomal translocation in a small cell osteosarcoma // Virchows Arch.-2006.-Vol.448.-p.852−856.
- Noguera R., Triche T.J., Navarro S. et al. Dynamic model of differentiation in Ewing’s sarcoma cells // Lab. Invest.-1992.-Vol.62.-p.l43−151.
- Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia// Science.-1960.-Vol.132.-p. 1497.
- O’Donovan M., Russell J.M., O’Leary J.J., Gillan J.A., Lawler M.P., Gaffney E.F. Abl expression, tumour grade, and apoptosis in chondrosarcoma // Mol. Patjol.-1999.-Vol.52.-p.341−344.
- O’Neill A.J., Cotter T.G., Russell J.M., Gaffiiey E.F. Abl expression in human fetal and adult tissues, tumours, and tumour micro vessels // J. Pathol.-1997.-Vol.l83.-p.325−329.
- Ochi K., Daigo Y., Katagiri T. et al. Predict of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles // Int. J. 0ncol.-2004.-Vol.24.-p.647−655.
- Ochi K., Daigo Y., Katagiri T. et al. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles // Int. J. 0ncol.-2004.-Vol.24.-p.647−655.
- Ohyama K., Chung C.H., Chen E. et al. p53 influences mice skeletal development // J. Craniofac. Genet. Dev. Biol.-1997.-Vol.17.-p. 161−171.
- Okada K., Frassica F.J., Sim F.H. et al. Parosteal osteosarcoma. A clinicopathological study // J. Bone Joint Surg. Am.-1994.-Vol.76.-p.366−378.
- Okada K., Unni K.K., Swee R.G., Sim F.H. High grade surface osteosarcoma: a clinicopathologic study of 46 cases // Cancer.-1999.-Vol.85.-p.l044−1054.
- Olive K.P., Tuveson D.A., Ruhe Z.C. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome // Cell.-2004.-Vol.l 19.-p.847−860.
- Oliveira A. M. 14th International Surgical Pathology Symposium May 2−5, 2007, Vienna, Austria. Lectures.
- Oliveira A.M., Nascimento A.G., Lloyd R.V. Leptin and leptin receptor mRNA are widely expressed in tumors of adipocytic differentiation // Mod. Pathol.-2001.-Vol.l4.-p.549−555.
- Oliver J.D., Kinzler K.W., Meltzer P. S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas // Nature.-1992.-Vol.358.-p.80−83.
- Onda M., Matsuda S., Higaki S. et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma // Cancer.-1996.-Vol.77.-p.71−78.
- Orizik Y.Y., Meloni A.M., Spanier S.S., Bush C.H., Kingsley K.L., Sandberg A.A., Deletion lp in a low-grade chondrosarcoma in a patient with Oilier disease // Cancer Genet. Cytogenet.-1998.-Vol.l05.-p.l28−133.
- Overall C.M. Regulation of tissue inhibitor of matrix metalloproteinase expression // Ann. New York Acad. Sci.-1994.-Vol.732.-p.51−64.
- Overholtzer M., Rao P.H., Favis R. et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability // Proc. Natl. Acad. Sci. USA.-2003.-Vol.l00.-p.l 1547−11 552.
- Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling // Nat. Rev. Mol. Cell Biol.-2007.-Vol.8.-p.221−233.
- Pan Z.K., Christiansen S.C., Ptasznik A., Zuraw B.L. Requirement of phosphatidylinositol 3-kinase/Akt for bradykinin stimulation of NF-Dappa B activation in cultured human epithelial cells // J. Biol. Chem.-1999.-Vol.274.-p.9918−9922.
- Papachristou D.J., Batistatou A., Sykiotis G.P., Varakis I., Papavassilou A.G. Activation of the JNK-AP-1 signal transduction pathway is associated withpathogenesis and progression of human osteosarcomas // Bone.-2003.-Vol.32.-p.364−371.
- Parada L.F., Tabin C.J., Shih C., Weiberg R.A. Human EJ bladder carcinoma oncogene is homologue of Havey sarcoma virus ras gene // Nature.-1982.-Vol.297.-p.474−478.
- Park H.-R., Min K., Kim H.-S., Jung W.W., Park Y.-K. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas // Pathology Research and Practice.-2008.-Vol.204.-p.575−582.
- Parrish J.E., Wagner M.J., Hecht J.T., Scott C.I.Jr., Well D.E. Molecular analysis of overlapping chromosomal deletions in patients with Langer-Giedion syndrome // Genomics.-1991.-Vol. 11.-p. 54−61.
- Pathology and Genetics of Tumors of Soft Tissue and Bone Tumours of soft tissue and bone. Pathology and Genetics // Rds. Ch.D.M.Fletcher et al.-WHO, Lyon.-2002.
- Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer // J. Clin. 0ncol.-2003.-Vol.21.-p. 1174−1179.
- Peydro-Olaya A., Llombart-Bosch A., Carda-Batalla C. et al. Electron microscopy and other ancillary techniques in the diagnosis of small round cell tumors // Semin. InDiagn. Pathol.-2003.-Vol.2, N.l.-p.25−45.
- Pilbeam C.C., Harrison J.R., Raisz L.G. Prostaglandins and bone metabolism. In: Bilezikian J.P., Raisz L.G., Rodan G.A., editors. Principles of bone biology. New York: Academic Press- 2002.-p.979−994.
- Pollack J.R., Perou C.M., Alizadeh A. A. et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays // Nat. Genet.-1999.-Vol.23.-p.41−46.
- Pompetti F., Rizzo P., Simon R.M. et al. Oncogene alterations in primary, recurrent, and metastatic human bone tumors // J. Cell Biochem.-1996.-Vol.63.-p.37−50.
- Porter D.E., Simpson A.H. The neolastic pathogenesis of solitary and multiple osteochondromas //J. Pathol.-1999.-Vol.l88.-p.l 19−125.
- Posl M., Amling M., Werner M. et al. Osteosarcoma apoptosis and proliferation. Study of Bcl-2 expression//Pathologe.-1994.-Vol.l5.-p.337−344.
- Practical approach to proceccing osteosarcomas in the surgical pathology laboratory. Pediatr Dev Pathol 1998- 1:449).
- Quirke P., Mapstone N. The new biology: histopathology // Lancet.-1999.-354 (Suppl.l).-S. 126−131.
- Qureshi A.A., Shott S., Mallin B.A. et al. Current trends in the management of adamantinoma of long bones. An international study // J. Bone Joint Surg. Am.-2000.-Vol.82.-p.ll22-l 131.
- Rabbits T.H. Perspective: chromosomal translocations can affect genes controlling gene expression and differentiation why are these functions targeted? // J. Pathol.-1999.-Vol. 187.-p.39−42.
- Radig K., Schneider-Stock R., Mittler U., Neumann H.W., Roessner A. Genetic instability in osteoblastic tumors of the skeletal system // Pathol. Res. Pract.-1998.-Vol. 194.-p.669−677.
- Ragazzini P., Gamberi G., Banassi M.S. et al. Analysis of SAS gene and CDK4 and MDM proteins in low-grade osteosarcoma // Cancer Detect. Prev.-1999.-Vol.23.-p.l29−136.
- Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors // Curr. Oncol. Rep.-2004.-Vol.6, N.2.-p.96−102.
- Raskind W.H., Conrad E.U., Matsushita M. Frequent loss of heterozygosity for markers on chromosome arm lOq in chondrosarcomas // Genes Chromosomes Cancer.-1996.-Vol.16.-p. 138−143.
- Raskind W.H., Conrad E.U., Matsushita M. et al. Evaluation of locus heterogeneity and EXT1 mutations in 34 families with hereditary multiple exostoses // Hum. Mutat.-1998.-Vol.ll.-p.231−239.
- Ray J.M., Stetler-Stevenson W.G. The role of matrix metalloproteinases and their inhibitors in tumour invasion, metastasis and angiogenesis // Eur. Respir. J.-1994.-Vol.7.-p.2062−2072.
- Raymond A.K., Chawla S.P., Carrasco C.H., Ayala A.G., Fanning C.V., Grice B., Armen T., lager C., Papadopoulos N.E., Edeiken J. Osteosarcoma chemotherapy effect: a prognostic factor // Semin. Diagn. Pathol.-1987.-Vol.4.-p.212−236.
- Reid R. New developments in the diagnosis of chondrosarcoma // J. Pathol.-1991.-Vol.163.-p.93−94.
- Reid R., Barrett A., Hamblen D.L. Sclerosing epithelioid fibrosarcoma // Histipathology.-1996.-Vol.28.-p.451−455.
- Ried T., Baldini A., Rand T.C., Ward D.C. Simultaneous visualization or seven different DNA probes by in situ hybridization using combinatorial fluorescence and digital imaging microscopy // Proc. Natl. Acad. Sci. USA.-1992.-Vol.89.-p. 1388−1392.
- Robey P.G., Boskey A.L. Extracellular matrix and biomineralization of bone. In: Favus M.J., ed. Primer on the Metabolic Bone Desiases and Disoeders of
- Metabolism. 6th ed. American Society of Bone and Mineral Research.-2006.-p.12−19.
- Rodan S.B., Imai Y., Thiede M.A. et al. Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties // Cancer Res.-1987.-Vol.47.-p.4961−4966.
- Rodrigues N.I., Hoots W.K., Koshkina N.V. et al. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases // J. Pediatr. Hematol. 0ncol.-2008.-ol.30, N.7.-p.507−512.
- Rosenthal D.I., Schiller A.L., Mankin HJ. Chondrosarcoma: Correlation of radiologic and histologic grade // Radiology.-1984.-Vol.l50.-p.21−26.
- Rosier R.N., O’Keefe R.J., Teot L.A. et al. P-glycoprotein expression in cartilaginous tumors//J. Surg. Oncol.-1997.-Vol.65.-p.95−105.
- Rozeman L.B., Hameetman L., Cleton-Jansen A.-M., Taminiau A.H., Hogendoom P.C.W., Bovee J.V.M.G. Absence of IHH and retention of PTHrP signaling in enchonromas and central chondrosarcomas // J. Pathol.-2005.-Vol.205.-p.476−482.
- Ruley H.E. p53 and response to chemotherapy and radiotherapy. In: Devita V.T., Hellman S., Rosenberg S.A., editors. Important advanced in oncology. Philadelphia: Lippincott-Raven Publishers.-1996.-p.37−56.
- Sandberg A.A., Bridge J.A. The cytogenetics of bone and soft tissue tumors // Austin: R.G.Landes.-1994.
- Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors // Cancer Genet. Cytogenet.-2003 .-Vol. 145-.-p. 1 -30.
- Sandig V., Brand K., Herwig S., Lukas J., Bartek J., Strauss M., Adenovirally transferred p 16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death //Nat. Med.-1997.-Vol.3.-p.313−319.
- Sanerkin N.G. The diagnosis and grading of chondrosarcoma of bone: A combined cytologic and histologic approach// Cancer.-1980.-Vol.45.-p.582−594.
- Sawaoka H., Tsujii S., Tsujii M. et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo II Lab. Invest.-1999.-Vol.79.-p.1469−1477.
- Sawyer J.R., Swanson C.M., Lukacs J.L., Nicholas R.W., North P.E., Thomas J.R. Evidence of an association between 6ql3−21 chromosome aberrations and locally aggressive behavior in patients with cartilage tumors // Cancer.-1998.-Vol.82.-p.471−483.
- Scheel C., Schaefer K.L., Jauch A. et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas // 0ncogene.-2001.-Vol.20.-p.3835−3844.
- Schena M., Shalon D., Heller R., Chai A., Brown P.O., Davis R.W. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes // Proc. Natl. Acad. Sci. USA.-1996.-Vol.93.-p.l0614−10 619.
- Schmale G.A., Conrad E.U. 3rd, Raskind W.H. The natural history of hereditary multiple exostoses // J. Bone Joint Am.-1994.-Vol.76.-p.986−992.
- Schofield D., Triche T.J. cDNA microarray analysis of global gene expression in sarcomas // Curr. Opin. Oncol.-2002.-Vol.l4.-p.406−411.
- Schofield D., Wai D., Triche T.J. Expression profiling of bone tumors. In: Ladanyi M., Gerald W.L., eds. Expression profiling of human tumors. Diagnostic and research applications. Totawa N.J.: Humana Press.-2003.-p.359−391.
- Scholz R.B., Christiansen H., Kabisch H., Winkler K. Molecular markers in the evaluation of bone neoplasms. In: Helliwell T.R., ed. Pathology of bone and joint neoplasms. Philadelphia: W.B.Saunders.-1999.-p.79−105.
- Schrage Y.M., Machado I., Meijer D. et al. COX-2 expression in chondrosarcoma: a role for celecoxib treatment // Eur. J. Cancer. (Epub. ahead of print).
- Schrock E., du Manoir S., Veldman T. et.al. Multicolor spectral karyotyping of human chromosomes // Science.-1996.-Vol.273.-p.494−497.
- Schuetz A.N., Rubin B.P., Goldblum J.R. et al. Intercellular junctions in Ewing’s sarcoma/primitive neuruectodermal tumor: additional evidence of epithelial differentiation // Mod. Pathol.-2005.-Vol.18.-p. 1403−1410.
- Schwab M., Alitalo K., Klempnauer K.H. et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour // Nature.-1983.-Vol.305.-p.245−248.
- Schwartz H.S., Dahir G.A., Butler M.G. Telomere reduction in giant cell tumor of bone and with aging // Cancer Genet. Cytogenet.-1993.-Vol.71.-p. 132 138.
- Schwartz S., Beisel J.H., Panny S.R., Cohen M.M. A complex rearrangement, including a deleted 8q, in a case of Langer-Giedion syndrome // Clin. Genet.-1985.-Vol.27.-p. 175−182.
- Scotlandi K., Baldini N., Oliviero M. et al. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors // Am. J. Pathol.-1996.-Vol.149.-p. 1209−1219.
- Scotlandi K., Manara M.C., Hattinger C.M. et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma // Eur. J. Cancer.-2005.-Vol.41 .-p. 1349−1361.
- Scotlandi K., Serra M., Manara M.C. et al. Clinical relevance of Ki-67 expression in bone tumors // Cancer.-1995.-Vol.75.-p.806−814.
- Selivanova G., Iotsova V., Okan I. et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from p53 C-terminal domain // Nat. Med.-1997.-Vol.3 .-p.632−63 8.
- Sengupta S., Harris C.C. p53: traffic cop at the crossroads of DNA repair and recombination//Nat. Rev. Mol. Cell Biol.-2005.-Vol.6.-p.44−55.
- Seo S.S., Song Y.S., Kang D.H. et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer // Gynecol. Oncol.-2004.-Vol.92.-p.927−935.
- Serra M., Scotlandi K., Reverter-Branchat G. et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in highgrade osteosarcoma of the extremities // J. Clin. 0ncol.-2003.-Vol.2 l.-p.536−542.
- Shen Z.N., Nishida K., Doi H. et al. Suprassion of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21 // Biochem. Biophys. Res. Commun.-2005.-Vol.328, N.2.-p.375−382.
- Sherr C.J. The INK4a/ARF network in tumour suppression // Mol. Cell Biol.-200 l.-Vol.2.-p.731−737.
- Sherr C.J., McCormick F. The RB and p53 pathways in cancer // Cancer Cell.-2002.-Vol.2.-p.l03−112.
- Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases // Genes. Dev.-1995.-Vol.9.-p.l 149−1163.
- Shih C.S., Wang L.S., Yang S.S. et al. DNA flow cytometric analysis of chest-wall chondroma and chondrosarcoma // Scand. J. Thorac. Cardiovasc. Surg.-1996.-Vol.30.-p. 157−161.
- Shushanov S., Bronstein M., Adelaide J., Jussila L., Tchipysheva T., Jacquemier J., Stavrovskaya A., Birnbaum D., Karamysheva A. VEGFc and VEGFR3 expression in human thyroid pathologies // Int. J. Cancer.-2000.-Vol.86, N.l.-p.47−52.
- Silberberg R. Ultrastructure of articular cartilage in health and disease // Clin. Orthop.-1968.-Vol.57.-p.233−257.
- Sim F.H., Unni K.K., Beabout J.W., Dahlin D.C. Osteosarcoma with small cells simulating Ewing’s tumor // J. Bone Joint Surg. Am.-1979.-Vol.61.-p.207−215.
- Simmons A.D., Musy M.M., Lopes C.S., Hwang L.Y., Yang Y.P., Lovett M. A direct interaction between EXT proteins and glycosyltransferases is defective in hereditary multiple exostoses // Hum. Mol. Genet.-1999.-Vol.8.-p.2155−2164.
- Sjogren H., Meis-Kindblom J.M., Kindblom L.G., Aman P., Stenman G. Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma // Cancer Res.-1999.-Vol.59.-p.5064−5067.
- Sjogren H., Meis-Kindblom J.M., Orndal C. et al. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma cytogenetic, molecular genetic, and cDNA microarray analyses //Am. J. Pathol.-2003.-Vol.162-p.781−792.
- Sledge G., Miller K. Angiogenesis and antiangiogenic therapy // Curr. Probl. Cancer.-2002.-Vol.26.-p. 1 -60.
- Smith L.M., Cox R.S., Donaldson S.S. Second cancers in long-term survivors of Ewing’s sarcoma. Clin Orthop Relat Res 1992 Jan, (274): 275−81.
- Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology // Annu. Rev. Biochem.-2000.-Vol.69.-p. 145−182.
- Somers G.R., Ho M., Zielenska M. et al. HER2 amplification and everexpression is not present in pediatric osteosarcoma. A tissue microarray study //Pediatr. Dev. Pathol.-2005.-Vol.8.-p.525−532.
- Soumaoro L.T., Uetake H., Higuchi T. et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer // Clin. Cancer Res.-2004.-Vol. 10.-p.8465−8471.
- Sounni N.E., Janssen M., Foidart J.M., Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis // Matrix Biol.-2003.-Vol. 22 (l).-P. 55−61.
- Speicher M.R., du Manoir S., Schrock E. et al. Molecular cytogenetic analysis of formalin-fixed, paraffin-embeded solid tumors by comparative genomic hybridization after universal DNA-amplification // Hum. Mol. Genet.-1993.-Vol.2.-p. 1907−1914.
- Speicher M.R., Gwyn Ballard S., Ward D.C. Karyotyping human chromosomes by combinational multi-fluor FISH // Nat. Genet.-1996.-Vol. 12.-p.368−375.
- Squire J. A., Pei J., Marrano P. et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use CGH analysis of cDNA microarrays // Genes Chromosomes Cancer.-2003.-Vol.38.-p.215−225.
- Staals E.L., Bacchini P., Mercuri M., Bertoni F. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas // J. Bone Joint Surg. Am.-2007.-Vol.89, N.5.-p.987−993.
- Staege M., Hutter Ch., Neumann I. et al. DNA microarrays reveal relationship of Ewing’s family tumors to both endothelial and neural crest-derived cells and define novel targets // Cancer Res.-2004.-Vol.64.-p.8213−8221.
- Stock C., Kager L., Fink F.M., Gadner H., Ambros P.F. Chromosomal regions involved in the pathogenesis of osteosarcomas // Genes Chromosomes Cancer.-2000.-Vol.28.-p.329−336.
- Storz P. Reactive oxygen species in tumor progression // Front Biosci.-2005.-Vol. 10.-p. 1881 -1896.
- Street J., Bao M., Guzman L. et al. Vascular Endothelial Growth Factor stimulates bone repair by promoting angiogenesis and bone turnove // Proc. Natl. Acad. Sci. USA.-2002.-Vol.99, N.15.-p.9656−9661.
- Sutton K.M., Wright M., Fondren G. et al. Cyclooxygenase-2 expression in chondrosarcoma // Oncology.-2004.-Vol.44, N.4.-p.275−280.
- Szendroi M: Giant-cell tumor of bone // J. Bone Joint Surg. (Br).-2004.-Vol.86.-p.5−12.
- Takahashi K., Kimura Y., Naito M., Yoshimura T., Uchida H., Araki S. Inflammatory fibrous histiocytoma presenting leukemoid reaction // Pathol. Res. Pract.-1989.-Vol.l84.-p.498−506.
- Tang Ch.-H., Tamamoto A., Lin Y.-T. et al. Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcoma metastasis // Biochem. Pharmacol.-2009 (article in press).
- Tarkkanen M., Bohling T., Helio H., Karaharju E., Kaipainen A. Szymanska J., Elomaa I., Knuutila S. A recurrent chondromyxoid fibroma with chromosome aberration ins (5−2)(ql3-pl2p25) and 2p deletion // Cancer Genet. Cytogenet.-1993.
- Tarkkanen M., Elomaa I., Blomqvist C. et al. DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma // Int. J. Cancer.-1999.-Vol.84.-p. 114−121.
- Tarkkanen M., Knuutila S. The diagnostic use of cytogenetic and molecular genetic techniques in the assessment of small round cell tumors // Curr. Diagnostic. Pathol.-2002.-Vol.8.-p.33 8−348.
- Temin H.M. The protovirus hypothesis: speculations on the significance of RNA-directed DNA synthesis for normal development and for caecinogenesis // J. Natl. Cancer Inst.-1971.-Vol.46.-p.3−7.
- Terek R.M., Healey J.H., Garin-Chesa P., Mak S., Huvos A., Albino A.P. p53 mutations in chondrosarcoma // Diagn. Mol. Pathol.-1998.-Vol.7.-p.51−56.
- Teyssier J.R., Ferre D., Frequent clonal chromosomal changes in human non-malignant tumors // Int. J. Cancer.-1989.-Vol.44.-p.828−832.
- The I., Bellaiche Y., Perrimon N. Hedgehog movement is regulated through tout velu-dependent synthesis of a heparin sulfate proteoglycan // Mol. Cell.-1999.-Vol.4.-p.633−639.
- Thomas D.G., Giordano T.J., Sanders D. et al. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma // Clin Cancer Res.-2002.-Vol.8.-p.788−793.
- Tiemann F., Hinds P.W. Induction of DNA synthesis and apoptosis by regulated inactivation of a temperature-sensitive retinoblastoma protein // EMBO J.-1998.-Vol.17.-p. 1040−1052.
- Tiet T.D., Alman B.A. Developmental pathways in musculoskeletal neoplasia: involvement of the Indian Hedgehog-parathyroid hormone-related protein pathway // Pediatr. Res.-2003.-Vol.53.-p.539−543.
- Tjiio J.H., Levan A. The chromosome number of man // Hereditas.-1956.-Vol.42.-p.l-6.
- Toguchida J., Yamaguchi T., Ritchie B. et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas // Cancer Res.-1992.-Vol.52.-p.6194−6199.
- Torchia E.C., Jaishankar S., Baker S.J. Ewing’s tumor fusion proteins block the differentiation of pluripotent marrow stromal cells // Cancer Res.-2003.-Vol.63.-p.3464−3468.
- Toriyama M., Rosenberg A.E., Mankin H.J., Fondren T., Treadwell B.V., Towle C.A. Matrix metalloproteinase digestion of aggrecan in human cartilage tumours //Eur. J. Cancer.-1998.-Vol.34.-p. 1969−1973.
- Trieb K., Gerth R., Holzer G. et al. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy // Br. J. Cancer.-2000.-Vol.82.-p.85−87.
- Trieb K., Kotz R. Proteins expressed in osteosarcoma and serum levels as prognostic factors // Int. J. Biochem. Cell Biol.-2001.-Vol.33.-p.ll-17.
- Trieb K., Lechleitner T., Lang S. et al. Heat-shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy // Hum. Pathol.-1998.-Vol.29.-p. 1050−1055.
- Trump B.F., Jones T.R. Diagnostic Electron Microscopy, Copyright 1980 by John Wiley and Sons, Inc.
- Tsai J.Y., Aviv H., Benevenia J. et al. HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis // Cancer Invest.-2004.-Vol.22.-p. 16−24.
- Tsai J.Y., Aviv H., Benevenia J. et al. HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis // Cancer Invest.-2004.-Vol.22.-p. 16−24.
- Tseng C.H. Atlas of ultrastructure. Ultrastructural Features In Pathology. Copyright 1980 by Appleton-Century-Crofts.
- Tsuchiya T., Sekine K.-ichi, Hinohara Sh.-ichi et al. Analysis of the pl6INK4, pl4ARF, pl6, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing’s sarcoma // Cancer Genet. Cytogenet.-2000.-Vol. 154.-p.91−98.
- Tsujii M., Kawano S., Tsujii S. et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells // Cell.-1998.-Vol.93.-p.705−716.
- Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria // J. Cell Physiol.-2003.-Vol. 195.-p. 158−167.
- Tsuneyoshi M., Dorfman H.D., Bauer T.W. Epithelioid hemangioendothelioma of bone. A clinicopathologic, ultrastructural, and immunohistichemical study // Am. J. Surg. Pathol.-1986.-Vol.l0.-p.754−764.
- Tung-Ping Poon R., Sheung-Tat F., Wong J. Clinical implications of circulating angiogenic factors in cancer patients // J. Clin. Onc.-2001.-Vol.4.-p.1207−1225.
- Ulaner G.A., Huang H.Y., Otero J. et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma // Cancer Res.-2003.-Vol.63.-p. 1759−1763.
- Unni K.K., Dahlin D.C. Osteosarcoma: pathology and classification // Semin. Roentgenol.-1989.-Vol.24.-p. 143−152.
- Unni K.K. 13th International Surgical Pathology Symposium, May 2−5, Lectures, Treviso, Italy.-2006.
- Urakawa H., Nishida Y., Naruse T. et al. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study // Clin. Orthop. Relat. Res.-2009.-Vol.467, N.ll.-p.2932−2938.
- Varley J.M., Evans D.G., Birch J.M. Li-Fraumeni syndrome a molecular and clinical review//Br. J. Cancer.-1997.-Vol.76.-p.l-14.
- Vasishta R.K., Gupta N., Kakkar N. et al. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma // J. Cancer Res. Ther.-2006.-Vol.2.-p.20−23.
- Vogelstein B., Kinzler K.W. p53 function and dysfunction // Cell.-1992.-Vol.70.-p.523−526.
- Vogelstein B., Lane D., Levine A.J. Surfing the p53 network // Nature.-2000.-Vol.408.-p.307−310.
- Wadayama B., Toguchida J., Yamaguchi T. et al. p53 expression and its relationship to DNA alterations in bine and soft tissue sarcomas // Br. J. Cancer.1993.-Vol.68.-p.l 134−1139.
- Wai D.H., Schaefer K.L. Schramm A. et al. Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays // Int. J. 0ncol.-2002.-Vol.20.-p.441−451.
- Wang L.L. Biology of osteogenic sarcoma // The Cancer J.-2005.-Vol.11, N.4.-p.294−305.
- Wei G., Antonescu C., de Alava E. et al. Prognostic impact of INK4A deletion in Ewing’s sarcoma // Cancer.-2000.-Vol.89.-p.793−99.
- Wei G., Lonardo F., Ueda T. et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and maping of 12ql3 amplicons // Int. J. Cancer.-1999.-Vol.80-p. 199−204.
- Weiss K.R., Cooper G.M., Jadlowiec J.A. et al. VEGF and BMP expression in mouse osteosarcoma cells // Clin. Orthop. Relat. Res.-2006.-Vol.450.-p.l 11−117.
- Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion // Faseb J.-1999.-Vol.l3, N.8.-p.781−792.
- Willen H. Fine needle aspiration in the diagnosis of bone tumors // Acta Orthop. Scand. Suppl.-1997.-Vol.273.-p.47−53.
- Wold L. Dedifferentiated chondrosarcoma // 10th Mayo Clinic International Surgical Pathology Symposium, Dublin.-2003.
- Wolf M., El-Rifai W. Tarkkanen M. et al. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray // Cancer.-Genet. Cytogenet.-2000.-Vol. 123.-p. 128−132.
- Wong E., DeLuca C., Boily C. et al. Characterization of autocrine inducible prostaglandin H synthasa-2 (PGHS-2) in human osteosarcoma cells // Inflamm. Res.-1997.-Vol.46.-p.51−59.
- Wong F.P., Boice J.DJr., Abramson D.H. et al. Cancer incidence after retinoblastoma // Radiation dose and sarcoma risk // JAMA.-1997.-Vol.278.-p.1262−1667.
- Wu Y.Q., Badano J.L., McCaskill C., Vogel H., Potocki L., Shaffer L.G. Haploinsufficiency of ALX4 as a potential cause of parietal foramina in the llpll.2 contiguous gene-deletion syndrome // Am. J. Hum. Genet.-2000.-Vol.67.-p.1327−1332.
- Wunder J.S., Eppert K., Burrow S.R. et al. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcoma // Oncogene.-1999.-Vol.l8.-p.783−788.
- Wunder J.S., Gokgoz N., Parkes R. et al. Tp53 mutations and outcome in osteosarcoma: a prospective, multicenter study // J. Clin. Oncol.-2005.-Vol.23.-p.1483−1490.
- Wunder J.S., Paulian G., Huvos A.G., Heller G., Meyers P.A., Healey J.H. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma // J. Bone Joint Surg. Am.-1998.-Vol.80.-p.1020−1033.
- Wunder J.S., Czitrom A.A., Kandel R., Andrulis I.L. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas // J. Natl. Cancer Inst.-1991.-Vol.83.-p. 194−200.
- Xia Sh.J., Barr F.G. Chromosome translocations in sarcomas and the emergence of oncogenic transcription factors // Eur. J. Cancer.-2005.-Vol.41.-p.2513−2527.
- Xu Z., Choudhary S., Voznesensky O. et al. Overexpression of Cox-2 human osteosarcoma cells decreases proliferation and increased apoptosis // Cancer Res.-2006.-Vo.66.-p.6657−6664.
- Yamaguchi T., Suzuki S., Ishiiwa H. et al. Benign notochordal cell tumors: a comparative study of benign notochordal cell tumors, classic chordomas, and notochordal vestiges of fetal intervertebral discs // Am. J. Surg. Pathol.-2004.
- Yamaguchi T., Toguchida J., Wadayama B. et al. Loss of geterozygosity and tumor suppressor gene mutations in chondrosarcomas // Anticancer Res.-1996.-Vol. 16.-p.2009−2015.
- Yang S.Y., Yu H., Krygier J.E., Wooley P.H., Mott M.P. High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model // Sarcoma.-2007: 95 628.
- Yang, E., Korsmeyer S.J. Molecular thanatopsis: a discourse on the Bcl2 family and cell death // Blood.-1996.-Vol.88.-p.386−401.
- Yin D., Jia T., Gong W. et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma //Int. J. Oncol.-2008.-Vol.33.-p.253−259.
- Yu C., Le A.T., Yeger H., Perbal B., Alman B.A. NOV (CCN3) regulation in the growth plate and CCN family member expression in cartilage neoplasia // J. Pathol.-2003 .-Vol.201 .-p.609−615.
- Yudoh K., Matsui H., Kanamori M., Ohmori K., Tsuji H., Tatezaki S. Serum levels of laminin, type IV collagen and type III procollagen peptide as markers for detection of metastasis // Jpn. J. Cancer Res.-1994.-Vol.85, N.12.-p.l263−1269.
- Yukata K., Matsui Y., Goto T., Kubo T., Yasui N. Differential expression of VEGF isoforms and VEGF receptors in cartilaginous tumors // Anticancer Res.-2005.-Vol.25.-p.955−957.
- Zamzami N., Susin S.A., Marchetti P., Hirsch T., Gomez-Monterrey I., Castedo M., Kroemer G. Mitochondrial control of nuclear apoptosis // J. Exp.
- Med.-1996.-Vol. 183 .-p. 1533−1544.
- Zhang H., Oliveira A.M. Fusion genes in epithelial neoplasia. J.Clin. Pathol.2010 Jan- 63(1):4−11 Epub 2009 Jul 28.
- Zheng M.H., Xu J., Robbins P. et al. Gene Expression of Vascular Endothelial Growth Factor in giant cell tumors of bone // Hum. Pathol.-2000.-Vol.31, N.7.-p.804−812.
- Zhou H., Randall R.L., Brothman A.R. et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification//J. Pediatr. Hematol. Oncol.-2003.-Vol.25-p.27−32.